Anti−PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1

INTRODUCTION: Novel anticancer therapies include anti–programmed cell death protein-1 (PD-1) and anti–programmed death ligand-1 (PD-L1) drugs. These novel medications have side effects in different organs, including the kidney. The most common adverse effect in the kidney is acute interstitial nephr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Kidney Int Rep
Autors principals: Cassol, Clarissa, Satoskar, Anjali, Lozanski, Gerard, Rovin, Brad, Hebert, Lee, Nadasdy, Tibor, Brodsky, Sergey V.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Translational Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6698303/
https://ncbi.nlm.nih.gov/pubmed/31440705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2019.06.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars